May Cho (@MayCho_MD) profile picture

GI oncologist and researcher @UCIAntiCancer. Tweets are my own opinions. RTs are not commercial endorsements.

Joined September 2017
Photo by May Cho (@MayCho_MD)Photo by May Cho (@MayCho_MD)Photo by May Cho (@MayCho_MD)Photo by May Cho (@MayCho_MD)Photo by May Cho (@MayCho_MD)Photo by May Cho (@MayCho_MD)Photo by May Cho (@MayCho_MD)Photo by May Cho (@MayCho_MD)Photo by May Cho (@MayCho_MD)Photo by May Cho (@MayCho_MD)
Three journeys of young onset colorectal cancers! “Dr. Cho told me to let her worry about the cancer and for me to worry about starting my brewery,” he recalled. Trinity County Brewing Company @TrinityBrewery opened in May 2020! health.ucdavis.edu/synthesis… @sepideh_gholami @HalabiMd
1
1
3
25
ctDNA-based MRD & survival in resectable CRC @NatureMedicine doi.org/10.1038/s41591-024-0… 🔎CIRCULATE-🇯🇵 GALAXY, 2,240 pts 👉shorter DFS in MRD+ patients 👉Better outcome after sustained ctDNA clearance in response to ACT 🧐What else do we need to implement into clinical practice? @myESMO
1
30
2
81
9,378
Clinical Outcomes of Elective Early Discontinuation of Immunotherapy Based on Objective Response in Microsatellite … pubmed.ncbi.nlm.nih.gov/3925… Our single center experience as summarized by our super Fellow Dr. Annie Xioa supports early discontinuation in settings of Clinical CR.
2
1
10
1,025
I will be riding in my 6th closer to free bike ride on 9/7/2024. The ride is a great experience to join the Yale Cancer Center community and support cancer research. Please support my ride at the following link: rideclosertofree.org/partici… My goal is to raise at least $500!
2
9
733
From @asco as led by: @ajscott40 @sepidah_gholami @MyriamChalabi @HKennecke @MayCho_MD @manjuggm @JoshSmithMDPhD : Management of Locally Advanced Rectal Cancer: ASCO Guideline pubmed.ncbi.nlm.nih.gov/3911… #crcsm #rectalcancer #cancer #CancerResearch @OncoAlert
7
19
1,550
Universe listens to your inner voice. Been wanting to meet this inspiring @realbowtiedoc and got a chance to have “peer mentoring” session and learned how he’s improving much needed pall care for GI Onc pts since the first day of their journeys!
A favorite #SuppOncSelfies📸 with luminary @MayCho_MD at @ASCOTECAG lounge. These 1-on-1 mentoring sessions are so cherished. Her wisdom "That queasy feeling you get is moving from a comfort to a growth mindset" So honored to have time at the table with her #ASCO24 #GIonc
14
505
💊Adding durvalumab plus bevacizumab to TACE in unresectable HCC EMERALD-1, @ASCO GI24 @JCO_ASCO ✅D+B+TACE vs TACE mPFS: 15.0 vs 8.2 mo, HR: 0.77 (0.61–0.98) p=0.032 ❌D+TACE vs TACE mPFS: 10.0 vs 8.2 mo, HR: 0.94 (0.75–1.19) p=0.638 👉ascopubs.org/doi/10.1200/JCO… ⁉️Whether it may change the practice may depend on OS. Patients continue to be followed for OS @JCOPO_ASCO @liver_cancer @BCLC_group @TimGreten @kmody29 @Amitmahipal79 @AndrewMMoon #cancer #oncology #liver #hcc #MedX
5
16
57
5,262
In MSI high mCRC Ipi Nivo was dramatically superior to chemo first line with marked improved PFS. Results of Nivo alone awaited. Establishes a new first line option in MSI high mCRC.
4
26
1,195
Liver Metastases & Immune Checkpoint Inhibitor Efficacy in Refractory mCRC @JAMANetworkOpen doi.org/10.1001/jamanetworko… 🔎CCTG CO.26 trial 👉Pts without LM have significantly improved DCR, PFS & OS with Durva/Treme vs BSC 🧐consistent finding, important for future trial design @myESMO
2
31
1
77
12,626
Yet another clinical trial failure by applying “targeted” therapy in an un-targeted fashion. While some cancer type have germ-line mutations (e.g., BRCA) which allow broader use of this drug class, NSCLC is not one of them. Even when BRCA-mutated, in NSCLC most are mono-allelic – at California, USA
Press release: Phase III KEYLYNK-008 closes for futility. Addition of maintenance olaparib (PARP inhibitor) after first-line pembrolizumab + chemotherapy in squamous NSCLC did not improve PFS or OS. Numerically longer PFS, not significant. Await details. businesswire.com/news/home/2…
2
15
40
6,796
I couldn’t be more proud of my fav partner-in-crime, amazing clinician and scientist, the best writer and human being…@jgong15. Nature for 5 yrs in and NEJM next! nature.com/articles/s41585-0…
1
2
1
12
2,421
We use a novel 2-mo RECIST organ-specific response assessment to dissect the impact of IO on responses in different sites of MSS MCRC. Check the article to learn more on how sites of metastases impact response. Liver, lung, peritoneum, and others- ejcancer.com/article/S0959-8…
1
4
20
1,535
Congrats @jtmoyers!!!🎉🎊 This is such an accomplishment within 6 months of arrival @AnglesClinic!!!
Molecular Templates First Patient Dosed Phase 1 Trial MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors - proud to have dosed the first patient and moved the story of anti-CTLA4 forward @angelesclinic @jtmoyers mtem.com/investors/news-even…
1
2
351
🎯Raludotatug deruxtecan R-DXd (CDH6 #AntibodyDrugCongugate) yields objective response rate of 46% and disease control rate of 98% in platinum resistant #OvarianCancer despite a median prior therapies of 4!! #ESMO2023 #gyncsm
2
55
11
171
57,184
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C | NEJM nejm.org/doi/full/10.1056/NE… Presidential ESMO session today by Dr. Pietrantonio! CodeBreaK 300 Phase 3 trial provides Level One Evidence for Soto + Pmab in KRAS G12C in refractory MCRC.
8
33
6
104
20,514
We think these recommendations will generate ideas for the next generation of #RectalCancer clinical trials. I appreciate leading this work with @PrajnanDasMD, @NCICTEP_ClinRes @CathyEngMD @KarynAGoodman ! – at Saint-Yrieix-le-Déjalat, France
Now out in @JNCI_Now! The consensus recommendations of the NCI Rectal-Anal Task Force members on the design of future clinical trials in rectal cancer. #crsm #rectalcancer @Hkennecke @CathyEngMD Read more here: doi.org/10.1093/jnci/djad143
1
13
1
22
9,076
“As a woman and a female scientist, I told my fellows; you can have both (a family and a career). You don’t need to over-assist your child. Your child will watch you and and they will do!”
“Ten years ago I was kicked out and forced to retire.” Our new medicine laureate Katalin Karikó (@kkariko) told us how much it means to be awarded the Nobel Prize after a scientific career that has been full of challenges. Ten years ago, Karikó was still doing all her experiments by hand but today she has been awarded the medicine prize for her research on mRNA, which led to the development of COVID-19 vaccines. Listen now:
6
463